dimethylamino vinyl methyl ketone | 56268-27-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: dimethylamino vinyl methyl ketone
• 英文别名: Dimethylaminovinylmethylketon；3-(Dimethylamino)but-3-en-2-one
• CAS: 56268-27-0
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: QDMQMVIMHGFILO-UHFFFAOYSA-N

物化性质

• 沸点：
  186.0±23.0 °C(Predicted)
• 密度：
  0.892±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  triethylgermyl dimethylamine 、 2,3-丁二酮 生成 dimethylamino vinyl methyl ketone
  参考文献：
  名称：

  Riviere-Baudet,M.; Satge,J., Recueil des Travaux Chimiques des Pays-Bas, 1975, vol. 94, p. 19 - 22

  摘要：

  DOI：

文献信息

• [EN] PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF<br/>[FR] PROMÉDICAMENTS DE PYRROLOBENZODIAZÉPINE ET CONJUGUÉS D'ANTICORPS DE CEUX-CI
  申请人：GENENTECH INC

  公开号：WO2018031662A1

  公开（公告）日：2018-02-15

  The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.

  这项发明涉及具有谷胱甘肽活化二硫键前药基团、DT-二氢呋喃酮酶活化醌前药基团或活化氧化物种的芳基硼酸或芳基硼酯前药基团的吡咯苯并二氮杂环烷单体和二聚体前药。该发明还涉及吡咯苯并二氮杂环烷前药二聚体-抗体共轭物。
• Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20030220330A1

  公开（公告）日：2003-11-27

  Compounds having activity as inhibitors of the JNK pathway are disclosed. The compounds of this invention are anilinopyrimidine derivatives having the following structure: 1 wherein R 1 through R 6 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明揭示了作为JNK通路抑制剂活性的化合物。本发明的化合物是具有以下结构的苯胺吡嘧啶衍生物：其中R1至R6如本文所定义。这些化合物在治疗对JNK通路抑制敏感的广泛疾病方面具有用途。因此，本文还揭示了治疗这些疾病的方法，以及含有上述化合物中的一个或多个化合物的药物组合物。
• Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20030203926A1

  公开（公告）日：2003-10-30

  Compounds having activity as inhibitors of IKK are disclosed, particularly IKK-2. The compounds of this invention are anilinopyrimidine derivatives having the following structure: 1 wherein R 1 and R 6 are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明揭示了作为IKK抑制剂的化合物，特别是IKK-2。本发明的化合物是具有以下结构的苯胺嘧啶衍生物：1其中R1和R6如本文所定义。这些化合物在治疗对IKK抑制有响应的各种疾病方面具有实用性。因此，本文还揭示了治疗这些疾病的方法，以及含有上述化合物之一或多个化合物的药物组合物。
• Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
  申请人：——

  公开号：US20040106634A1

  公开（公告）日：2004-06-03

  This invention generally relates to methods for treating or preventing a condition responsive to JNK inhibition, such as a metabolic condition, comprising administering to a patient in need thereof an effective amount of an Anilinopyrimidine Derivative having the following structure: 1 or a pharmaceutically acceptable salt thereof, wherein R 1 through R 6 are as defined herein.

  这项发明通常涉及用于治疗或预防对JNK抑制敏感的疾病的方法，例如代谢状况，包括向需要的患者施用具有以下结构的Anilinopyrimidine衍生物的有效剂量：1或其药用可接受盐，其中R1至R6如本文所定义。
• METHOD FOR THE PREPARATION OF 3-FLUOROALKYL-1-METHYLPYRAZOL-4-CARBOXYLIC ACID
  申请人：SOLVAY FLUOR GmbH

  公开号：US20180273486A1

  公开（公告）日：2018-09-27

  The present invention relates to method for the preparation of 3-fluoroalkyl-1-methylpyrazol-4-carboxylic acid, wherein it comprises the following steps: step 1, fluoroacetyl fluoride derivative shown in Formula I undergoes condensation with dimethylamino vinyl methyl ketone, as a result, 3-dimethylamino methylene-fluoro-2,4-pentanedione derivative shown in Formula II is formed; step 2, ring closing reaction takes place between said 3-dimethylamino methylene-fluoro-2,4-pentanedione shown in Formula II and methylhydrazine, in this way, 3-fluoroalkyl-1-methyl-4-acetyl pyrazol derivative shown in Formula III is obtained; step 3, the said 3-fluoroalkyl-1-methyl-4-acetyl pyrazol derivative shown in Formula III is oxidized in the presence of alkali, and then acidified, in this way, 3-fluoroalkyl-1-methylpyrazol-4-carboxylic acid shown in Formula IV is formed. Preparing method of present invention, wherein the required preparing route is simple, the raw material cost is low, the resulting yield of each step is high, and it is suitable for industrialization.

  本发明涉及一种制备3-氟烷基-1-甲基吡唑-4-羧酸的方法，其中包括以下步骤：步骤1，式I所示的氟乙酰氟衍生物与二甲基氨基乙烯基甲基酮发生缩合反应，从而形成式II所示的3-二甲基氨基亚甲基-氟-2,4-戊二酮衍生物；步骤2，式II所示的3-二甲基氨基亚甲基-氟-2,4-戊二酮与甲基肼发生环合反应，得到式III所示的3-氟烷基-1-甲基-4-乙酰吡唑衍生物；步骤3，式III所示的3-氟烷基-1-甲基-4-乙酰吡唑衍生物在碱的存在下被氧化，然后酸化，从而形成式IV所示的3-氟烷基-1-甲基吡唑-4-羧酸。本发明的制备方法，所需制备路线简单，原料成本低，每个步骤的产率高，适合工业化生产。